Considerations for Cancer-Directed Therapy in Advanced Childhood Cancer

  • Angela M. FeracoEmail author
  • Luca Manfredini
  • Momcilo Jankovic
  • Joanne Wolfe
Part of the Pediatric Oncology book series (PEDIATRICO)


Cancer-directed therapy encompasses any modality utilized with the goal of controlling cancer. Research among adults with advanced cancer suggests that adults who understand that their cancer is incurable are less likely to continue cytotoxic cancer-directed therapy. However, novel classes of targeted and immunologic therapies are rapidly changing treatment paradigms in advanced malignancies. These agents may alter previously accepted prognostic estimates for some advanced cancers by facilitating life extension through cancer control without achieving cancer eradication. Similarly, our understanding of illness trajectories in advanced childhood cancers is increasingly complex and necessitates nuanced and serial prognostic discussions. Research among families of children with advanced cancer suggests that preferences and priorities vary and that cancer-directed therapy may convey benefits as well as burdens. In summary, detailed understanding of tumor biology, available therapies and healthcare system constraints, careful symptom monitoring, and repeated assessments of patient and parent understanding, preferences, and goals should guide decision-making with regard to selecting, continuing, or discontinuing cancer-directed therapy.


Cancer-directed Therapy Childhood Cancer Prognostic Discussions Illness Trajectory Time-limited Trial 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Bluebond-Langner M, Belasco JB, Goldman A, Belasco C (2007) Understanding parents’ approaches to care and treatment of children with cancer when standard therapy has failed. J Clin Oncol 25(17):2414–2419CrossRefPubMedGoogle Scholar
  2. Bluebond-Langner M, Belasco JB, DeMesquita Wander M (2010) “I want to live, until I don’t want to live anymore”: involving children with life-threatening and life-shortening illnesses in decision making about care and treatment. Nurs Clin North Am 45(3):329–343CrossRefPubMedGoogle Scholar
  3. Chou AJ, Merola PR, Wexler LH et al (2005) Treatment of osteosarcoma at first recurrence after contemporary therapy: the Memorial Sloan-Kettering Cancer Center experience. Cancer 104(10):2214–2221CrossRefPubMedGoogle Scholar
  4. Feraco AM, Dussel V, Orellana L et al (2017) Tumor talk and child-well being: perceptions of “good” and “bad” news among parents of children with advanced cancer. J Pain Symptom Manage 53:833–841CrossRefPubMedGoogle Scholar
  5. Goldsby RE, Fan TM, Villaluna D et al (2013) Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the children’s oncology group. Eur J Cancer 49(10):2384–2391CrossRefPubMedPubMedCentralGoogle Scholar
  6. Hazen RA, Zyzanski S, Baker JN, Drotar D, Kodish E (2015) Communication about the risks and benefits of phase I pediatric oncology trials. Contemp Clin Trials 41:139–145CrossRefPubMedPubMedCentralGoogle Scholar
  7. Hill DL, Miller V, Walter JK et al (2014) Regoaling: a conceptual model of how parents of children with serious illness change medical care goals. BMC Palliat Care 13(1):9CrossRefPubMedPubMedCentralGoogle Scholar
  8. Hinds PS, Drew D, Oakes LL et al (2005) End-of-life care preferences of pediatric patients with cancer. J Clin Oncol 23(36):9146–9154CrossRefPubMedGoogle Scholar
  9. Howlader N, Noone AM, Krapcho M, et al (eds) (2017) SEER Cancer Statistics Review, 1975–2014. National Cancer Institute, Bethesda, MD., based on November 2016 SEER data submission, posted to the SEER web site
  10. Huo JS, Symons HJ, Robey N, Borowitz MJ, Schafer ES, Chen AR (2016) Persistent multiyear control of relapsed T-cell acute lymphoblastic leukemia with successive donor lymphocyte infusions: a case report. Pediatr Blood Cancer 63:1279–1282CrossRefPubMedPubMedCentralGoogle Scholar
  11. Kamihara J, Nyborn JA, Olcese ME, Nickerson T, Mack JW (2015) Parental hope for children with advanced cancer. Pediatrics 135(5):868–874CrossRefPubMedGoogle Scholar
  12. Kang TI, Hexem K, Localio R, Aplenc R, Feudtner C (2013) The use of palliative chemotherapy in pediatric oncology patients: a national survey of pediatric oncologists. Pediatr Blood Cancer 60(1):88–94CrossRefPubMedGoogle Scholar
  13. Kempf-Bielack B, Bielack SS, Jurgens H et al (2005) Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol 23(3):559–568CrossRefPubMedGoogle Scholar
  14. Levine DR, Mandrell BN, Sykes A et al (2017) Patients’ and parents’ needs, attitudes, and perceptions about early palliative care integration in pediatric oncology. JAMA Oncol doi: 10.1001/jamaoncol.2017.0368 (published online 9 March 2017 ahead of print)
  15. Mack JW, Joffe S (2014) Communicating about prognosis: ethical responsibilities of pediatricians and parents. Pediatrics 133(Suppl 1):S24–S30CrossRefPubMedGoogle Scholar
  16. Mack JW, Wolfe J, Grier HE, Cleary PD, Weeks JC (2006) Communication about prognosis between parents and physicians of children with cancer: parent preferences and the impact of prognostic information. J Clin Oncol 24(33):5265–5270CrossRefPubMedGoogle Scholar
  17. Mack JW, Joffe S, Hilden JM et al (2008) Parents’ views of cancer-directed therapy for children with no realistic chance for cure. J Clin Oncol 26(29):4759–4764CrossRefPubMedPubMedCentralGoogle Scholar
  18. Mack JW, Chen K, Boscoe FP et al (2015) High intensity of end-of-life care among adolescent and young adult cancer patients in the new york state medicaid program. Med Care 53(12):1018–1026CrossRefPubMedPubMedCentralGoogle Scholar
  19. Mauer AM (1987) The concept of cure in pediatric oncology. Altered realities. Am J Pediatr Hematol Oncol 9(1):58–61CrossRefPubMedGoogle Scholar
  20. Miller EG, Laragione G, Kang TI, Feudtner C (2012) Concurrent care for the medically complex child: lessons of implementation. J Palliat Med 15(11):1281–1283CrossRefPubMedGoogle Scholar
  21. Orkin SH (2015) Nathan and Oski’s hematology and oncology of infancy and childhood, 8th edn. Elsevier Saunders, Philadelphia, PAGoogle Scholar
  22. Pierce MI, Borges WH, Heyn R, Wolff JA, Gilbert ES (1969) Epidemiological factors and survival experience in 1770 children with acute leukemia treated by members of Children’s Study Group A between 1957 and 1964. Cancer 23(6):1296–1304CrossRefPubMedGoogle Scholar
  23. Pui CH, Cheng C, Leung W et al (2003) Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med 349(7):640–649CrossRefPubMedGoogle Scholar
  24. Rosenberg AR, Orellana L, Kang TI et al (2014) Differences in parent-provider concordance regarding prognosis and goals of care among children with advanced cancer. J Clin Oncol 32(27):3005–3011CrossRefPubMedPubMedCentralGoogle Scholar
  25. Sisk BA, Kang TI, Mack JW (2017) Prognostic disclosures over time: parental preferences and physician practices. Cancer doi: 10.1002/cncr.30716 (published online 3 April 2017 ahead of print)
  26. von Stackelberg A, Volzke E, Kuhl JS et al (2011) Outcome of children and adolescents with relapsed acute lymphoblastic leukaemia and non-response to salvage protocol therapy: a retrospective analysis of the ALL-REZ BFM study group. Eur J Cancer 47(1):90–97CrossRefGoogle Scholar
  27. von Stackelberg A, Locatelli F, Zugmaier G et al (2016) Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J Clin Oncol 34(36):4381–4389CrossRefGoogle Scholar
  28. The AM, Hak T, Koeter G, van Der Wal G (2000) Collusion in doctor-patient communication about imminent death: an ethnographic study. BMJ 321(7273):1376–1381CrossRefPubMedPubMedCentralGoogle Scholar
  29. Weeks JC, Cook EF, O’Day SJ et al (1998) Relationship between cancer patients’ predictions of prognosis and their treatment preferences. JAMA 279(21):1709–1714CrossRefPubMedGoogle Scholar
  30. Weeks JC, Catalano PJ, Cronin A et al (2012) Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med 367(17):1616–1625CrossRefPubMedPubMedCentralGoogle Scholar
  31. Wolfe J, Klar N, Grier HE et al (2000a) Understanding of prognosis among parents of children who died of cancer: impact on treatment goals and integration of palliative care. JAMA 284(19):2469–2475CrossRefPubMedGoogle Scholar
  32. Wolfe J, Grier HE, Klar N et al (2000b) Symptoms and suffering at the end of life in children with cancer. N Engl J Med 342(5):326–333CrossRefPubMedGoogle Scholar
  33. Wolfe J, Orellana L, Ullrich C et al (2015) Symptoms and distress in children with advanced cancer: prospective patient-reported outcomes from the PediQUEST study. J Clin Oncol 33(17):1928–1935CrossRefPubMedPubMedCentralGoogle Scholar
  34. Yu AL, Gilman AL, Ozkaynak MF et al (2010) Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med 363(14):1324–1334CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Angela M. Feraco
    • 1
    Email author
  • Luca Manfredini
    • 2
  • Momcilo Jankovic
    • 3
  • Joanne Wolfe
    • 4
  1. 1.Department of Pediatric OncologyDana-Farber Cancer Institute and Boston Children’s HospitalBostonUSA
  2. 2.Department of NeurosciencesPaediatric Chronic Pain and Palliative Care Service, Rehabilitation and Continuity of Care, Institute G. GasliniGenoaItaly
  3. 3.Department of Paediatric Haemato-OncologyMonza and Brianza Foundation for Children and Mothers, Hospital San GerardoMonzaItaly
  4. 4.Department of Psychosocial Oncology and Palliative CareDana-Farber Cancer InstituteBostonUSA

Personalised recommendations